Carl Zeiss Meditec, the medical technology firm based in the east German city of Jena, reported on Monday a lower revenue forecast for fiscal 2023-24 and a 3% drop in annual adjusted revenue for the first eight months of fiscal 2023-24.
The company said it now expects fiscal revenue of €2 billion ($2.14 billion) compared its previous expectation of €2.1 billion to €2.15 billion . This outlook excludes the contribution from the acquisition of the DORC, the Dutch Ophthalmic Research Center, which continues to be estimated at an additional €100 million for the second half of the fiscal year.
In the first 8 months of the fiscal year, the preliminary revenues were €1.258 billion, compared to €1.297 billion last year.
The company said Earnings Before Interest and Taxes (EBIT), excluding effects related to the DORC acquisition, will fall significantly short of the previously stated target of a comparable level to last year's €348.1 million and reach a level between around €215 million to €265 million.
Carl Zeiss Meditec plans to publish the quarterly statement for 9 months of 2023-24 on August 6.